Table 14.6
De Novo Posttransplant Solid Malignancy, 1996 to 2005
Kidney Recipients

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Total # of Post-Tx Malignancies	690	728	749	698	684	575	395	311	179	51
Malignancies by Type										
Squamous/Basal Cell Carcinoma	386	420	412	381	358	288	203	143	96	22
Melanoma	15	20	14	19	24	14	11	14	3	2
Kaposi Sarcoma	6	5	12	7	10	6	2	3	2	-
Central Nervous System	5	3	8	6	6	7	5	2	1	-
Genito-Urinary (1)	82	97	110	95	97	67	59	55	21	12
Gastro-Intestinal (2)	40	40	42	59	45	45	26	22	13	4
Primary Hepatic Tumor	6	8	8	4	8	6	5	-	2	1
Metastatic Hepatic Tumor	7	8	13	9	10	13	6	3	4	1
Larynx/Bronchi/Lung	57	42	47	51	45	52	26	26	13	5
Breast/Thyroid	40	41	39	32	37	36	24	23	7	1
Leukemia	3	3	3	3	4	7	4	2	4	1
Sarcoma (3)	1	1	3	2	-	3	-	1	2	-
Other	36	31	35	22	30	25	18	7	10	2
Unknown	6	9	3	8	10	6	6	10	1	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	55.9%	57.7%	55.0%	54.6%	52.3%	50.1%	51.4%	46.0%	53.6%	43.1%
Melanoma	2.2%	2.7%	1.9%	2.7%	3.5%	2.4%	2.8%	4.5%	1.7%	3.9%
Kaposi Sarcoma	0.9%	0.7%	1.6%	1.0%	1.5%	1.0%	0.5%	1.0%	1.1%	-
Central Nervous System	0.7%	0.4%	1.1%	0.9%	0.9%	1.2%	1.3%	0.6%	0.6%	-
Genito-Urinary (1)	11.9%	13.3%	14.7%	13.6%	14.2%	11.7%	14.9%	17.7%	11.7%	23.5%
Gastro-Intestinal (2)	5.8%	5.5%	5.6%	8.5%	6.6%	7.8%	6.6%	7.1%	7.3%	7.8%
Primary Hepatic Tumor	0.9%	1.1%	1.1%	0.6%	1.2%	1.0%	1.3%	-	1.1%	2.0%
Metastatic Hepatic Tumor	1.0%	1.1%	1.7%	1.3%	1.5%	2.3%	1.5%	1.0%	2.2%	2.0%
Larynx/Bronchi/Lung	8.3%	5.8%	6.3%	7.3%	6.6%	9.0%	6.6%	8.4%	7.3%	9.8%
Breast/Thyroid	5.8%	5.6%	5.2%	4.6%	5.4%	6.3%	6.1%	7.4%	3.9%	2.0%
Leukemia	0.4%	0.4%	0.4%	0.4%	0.6%	1.2%	1.0%	0.6%	2.2%	2.0%
Sarcoma (3)	0.1%	0.1%	0.4%	0.3%	-	0.5%	-	0.3%	1.1%	-
Other	5.2%	4.3%	4.7%	3.2%	4.4%	4.3%	4.6%	2.3%	5.6%	3.9%
Unknown	0.9%	1.2%	0.4%	1.1%	1.5%	1.0%	1.5%	3.2%	0.6%	-
Total # of Patients	488	506	550	509	487	432	311	255	158	48

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(-) = None in category.
(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.
(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.
(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.
Recipient malignancy statistics are based on voluntary reporting to the OPTN.